Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMUQO86)

• Drug Name: IM-491 Drug Info
• Synonyms: IM-491; UNII-UG82Y9C069; CHEMBL134908; UG82Y9C069; SCHEMBL6444631; BDBM50136259; 2,3-Piperidinedicarboxamide, N3-hydroxy-1-methyl-N2-(4-((2-methyl-4-quinolinyl)methoxy)phenyl)-, (2S,3S)-; 252918-63-1; (2S,3S)-N3-hydroxy-1-methyl-N2-(4-((2-methylquinolin-4-yl)methoxy)phenyl)piperidine-2,3-dicarboxamide; (2S,3S)-1-Methyl-piperidine-2,3-dicarboxylic acid 3-hydroxyamide 2-{[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-amide}

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 9889867
  CAS Number: CAS 252918-63-1
  TTD Drug ID: DMUQO86

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
TNF alpha converting enzyme (ADAM17)	TT6AZXG	ADA17_HUMAN	Inhibitor	[1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
TNF alpha converting enzyme (ADAM17)	DTT	ADAM17	4.995	5.443	5.278	5.225

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

• The Studied Disease: Discovery agent
• ICD Disease Classification: N.A.

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
TNF alpha converting enzyme (ADAM17)	DTT	ADAM17	3.03E-08	0.15	0.45

References

• [1] Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):241-6.